GT
MDGL icon

Glenmede Trust’s Madrigal Pharmaceuticals MDGL Stock Holding History

Glenmede Trust’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-772
Closed -$404K – 1537
2026
Q1 		$404K Buy
772
+81
+12% +$38.7K ﹤0.01% 1041
2025
Q4 		$402K Buy
+691
New +$353K ﹤0.01% 1019
2024
Q1 		– Sell
-1,066
Closed -$247K – 1371
2023
Q4 		$247K Sell
1,066
-501
-32% -$87.7K ﹤0.01% 1089
2023
Q3 		$229K Buy
1,567
+544
+53% +$102K ﹤0.01% 1068
2023
Q2 		$248K Hold
1,023
– – ﹤0.01% 1040
2023
Q1 		$248K Buy
+1,023
New +$279K ﹤0.01% 1045
2019
Q1 		– Sell
-68
Closed -$7K – 3130
2018
Q4 		$7K Buy
+68
New +$10.5K ﹤0.01% 2429

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Glenmede Trust's MDGL Position: Q2 2026 in Review

Glenmede Trust sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 772 shares — an estimated $404K sold.

Glenmede Trust first reported a position in MDGL in Q4 2018 and held it in 7 quarters. The position peaked at $404K in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Glenmede Trust reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Glenmede Trust sold 772 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $404K.
  • Glenmede Trust first reported a position in Madrigal Pharmaceuticals in Q4 2018 and held it in 7 quarters.
  • Glenmede Trust's Madrigal Pharmaceuticals position peaked at $404K in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.